相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer
Joanna M. Brell et al.
ONCOLOGY (2009)
Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-line Therapy for Patients With Advanced Pancreatic Cancer
Henry Q. Xiong et al.
CANCER (2008)
Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer
Stefan Boeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Validation of the 6th Edition AJCC Pancreatic Cancer Staging System - Report from the National Cancer Database
Karl Y. Bilimoria et al.
CANCER (2007)
A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer
L. S. Blaszkowsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer:: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study
J. Taieb et al.
ANNALS OF ONCOLOGY (2007)
Prognostic factors in patients with gemcitabine-refractory pancreatic cancer
Kohei Nakachi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Second-line chemotherapy in advanced pancreatic Carcinoma: a multicenter survey of the gruppo oncologico italia meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice
V. Gebbia et al.
ANNALS OF ONCOLOGY (2007)
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer
Christina Herrmann et al.
ONCOLOGY (2007)
Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
A Demols et al.
BRITISH JOURNAL OF CANCER (2006)
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study
N Tsavaris et al.
INVESTIGATIONAL NEW DRUGS (2005)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer
P Kozuch et al.
ONCOLOGIST (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
